Effect of HDL-raising drugs on cardiovascular outcomes: a systematic review and meta-regression.

ABSTRACT:

Background

Substantial residual cardiovascular risk remains after optimal LDL lowering in patients of established coronary artery disease. A number of therapeutic agents that raise HDL-C have been tested in clinical trials to cover this risk. However, the results of clinical trials are conflicting.

Objectives

To determine whether raising HDL-C with pharmacologic therapies translates into beneficial cardiovascular outcomes and to find out if this change was proportional to the percentage change in HDL levels.

Methods

Electronic and printed sources were searched up to August, 2013 for randomised controlled trials (RCTs) using at least one of the HDL raising therapies for secondary prevention of adverse cardiovascular events over optimal LDL levels. Data from eligible st

SUBMITTER: Kaur N 

PROVIDER: S-EPMC3984171 | biostudies-literature | 2014

REPOSITORIES: biostudies-literature